Objective: To evaluate the role of neutrop- hil-lymphocyte ratio in treatment resistance and follow-up in pregnant women with lower urinary tract infection.
Materials and Methods: The data of 88 pregnant women with UTI complaints betwe- en September 2016 and December 2018 were retrospectively reviewed. Patients with stone disease, JJ stent or nephrostomy placement, and urinary system anatomic malformation that complicate the etiology were excluded from the study. Patients were divided into two groups according to their first and third day medical treatment.
Results: Group A consisted of 64 patients with a mean age of 23.7 ± 4.7 years and group B consisted of 24 patients with 24.4 ± 6.0 years. The mean NLR at the first visit was 4.7 ± 1.2 in group A and 7.1 ± 1.9 in group B. In group B, this value was 6.7 ± 2.1 on the third day after empirical treatment and the difference was not statistically significant (p> 0.05). At the end of the treatment period, the mean NLR in group A decreased to 2.4 ± 1.0, and it decreased to 1.4 ± 0.6 in group B(P <0.05). The cutoff value for NLR was 6.15 (sensitivity 0.76, specificity 0.86, and P <0.001). When all patients were com- pared according to this cutoff value, 9 (14%) and 19 (79.1%) patients in group A had NLR levels above this value at the first admission (P <0.001).
Conclusion: NLR is a marker that can be useful to the clinician both in determining the treatment-resistant patient group and in follo- wing the response to treatment.
Keywords: Urinary tract infection; Neut- rophil-lymphocyte ratio; Pregnant
Abstract
Objective: To evaluate the role of neutrop- hil-lymphocyte ratio in treatment resistance and follow-up in pregnant women with lower urinary tract infection.
Materials and Methods: The data of 88 pregnant women with UTI complaints betwe- en September 2016 and December 2018 were retrospectively reviewed. Patients with stone disease, JJ stent or nephrostomy placement, and urinary system anatomic malformation that complicate the etiology were excluded from the study. Patients were divided into two groups according to their first and third day medical treatment.
Results: Group A consisted of 64 patients with a mean age of 23.7 ± 4.7 years and group B consisted of 24 patients with 24.4 ± 6.0 years. The mean NLR at the first visit was 4.7 ± 1.2 in group A and 7.1 ± 1.9 in group B. In group B, this value was 6.7 ± 2.1 on the third day after empirical treatment and the difference was not statistically significant (p> 0.05). At the end of the treatment period, the mean NLR in group A decreased to 2.4 ± 1.0, and it decreased to 1.4 ± 0.6 in group B(P <0.05). The cutoff value for NLR was 6.15 (sensitivity 0.76, specificity 0.86, and P <0.001). When all patients were com- pared according to this cutoff value, 9 (14%) and 19 (79.1%) patients in group A had NLR levels above this value at the first admission (P <0.001).
Conclusion: NLR is a marker that can be useful to the clinician both in determining the treatment-resistant patient group and in follo- wing the response to treatment.
Keywords: Urinary tract infection; Neut- rophil-lymphocyte ratio; Pregnant